BridgeBio is substantially advanced its progress of the innovative treatment for cardiac amyloidosis, leveraging the investigational drug. Preliminary trial data suggests significant outcomes for patients suffering with https://attr-cm818308.getblogs.net/74777049/firm-improves-cardiac-amyloidosis-treatment-with-attruby